2017-001739-38: A study to evaluate the safety and tolerability of TAK-831 in patients with schizophrenia. |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-831, Tablet | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003834-34: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia Estudio para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia |
|
|
| Ongoing | 2 | 308 | Europe | Luvadaxistat, NBI-1065844, Tablet | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Cognitive Impairment Associated With Schizophrenia Deterioro cognitivo asociado a la esquizofrenia, Cognitive Impairment and Schizophrenia Deterioro Cognitivo y Esquizofrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
| Terminated | 2 | 216 | Europe, US, RoW | Placebo, Luvadaxistat, NBI-1065844, TAK-831 | Neurocrine Biosciences, Neurocrine Biosciences, Inc. | Schizophrenia | 06/24 | 10/24 | | |
